Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Ataxin 1 antibody

This anti-Ataxin 1 antibody is a Mouse Monoclonal antibody detecting Ataxin 1 in IHC, ELISA, ICC and FACS. Suitable for Human. This Primary Antibody has been cited in 1 publication.
Catalog No. ABIN968970

Quick Overview for Ataxin 1 antibody (ABIN968970)

Target

See all Ataxin 1 (ATXN1) Antibodies
Ataxin 1 (ATXN1)

Reactivity

  • 79
  • 63
  • 35
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Human

Host

  • 67
  • 51
  • 1
Mouse

Clonality

  • 67
  • 52
Monoclonal

Conjugate

  • 50
  • 8
  • 7
  • 7
  • 5
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This Ataxin 1 antibody is un-conjugated

Application

  • 89
  • 44
  • 43
  • 35
  • 34
  • 25
  • 23
  • 23
  • 9
  • 6
  • 5
  • 1
  • 1
Immunohistochemistry (IHC), ELISA, Immunocytochemistry (ICC), Flow Cytometry (FACS)

Clone

2F5
  • Purpose

    ATXN1 Antibody

    Purification

    Ascitic fluid

    Immunogen

    Purified recombinant fragment of human ATXN1 expressed in E. Coli.

    Isotype

    IgG1
  • Application Notes

    ELISA: 1/10000

    FCM: 1/200 - 1/400

    ICC: 1/200 - 1/1000

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    Ascitic fluid containing 0.03 % sodium azide.

    Preservative

    Sodium azide

    Precaution of Use

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    4 °C,-20 °C

    Storage Comment

    Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
  • Lim, Crespo-Barreto, Jafar-Nejad, Bowman, Richman, Hill, Orr, Zoghbi: "Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1." in: Nature, Vol. 452, Issue 7188, pp. 713-8, (2008) (PubMed).

  • Target

    Ataxin 1 (ATXN1)

    Alternative Name

    ATXN1

    Background

    The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 41-81 CAG repeats, compared to 6-39 in the normal allele. At least two transcript variants encoding the same protein have been found for this gene.Tissue specificity: Widely expressed throughout the body.

    Molecular Weight

    87 kDa

    UniProt

    P54253

    Pathways

    Synaptic Membrane
You are here:
Chat with us!